Clinical trial · Observational
Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy
Axillary Lymph Node Identification Before Neoadjuvant Chemotherapy Using Magtrace, (Superparamagnetic Iron Oxide Nanoparticles, SPIO) and Magseed, in Clinically Node Negative and Node Positive Patients. SentiNeo 2.0
NCT06104371CI-TRIAL-00103844SentiNeo2recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Magnetic tracer injected before preoperative chemotherapy in breast cancer patients for sentinel lymph node detection. Also, magnetic tracer in combination with magnetic clip for index node identification.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magtrace | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Node negative
- description
- Clinically node negative before neoadjuvant chemotherapy
- interventionNames
- Device: Magtrace
- label
- Node positive
- description
- Clinically node positive before neoadjuvant chemotherapy
- interventionNames
- Device: Magtrace
Primary outcomes (1)
- measure
- Sentinel lymph node detection rate
- timeFrame
- Perioperatively
- description
- per patient
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion criteria: * Patients 18 years of age or older. * Patients with breast cancer planned to undergo NACT with * planned sentinel lymph node dissection (SLND), or * targeted axillary lymph node dissection (TAD), in conjunction with the * breast surgery after NACT. Exclusion Criteria: * Intolerance / hypersensitivity to iron or dextran compounds or SPIO. * Patients who are required to undergo MRI to evaluate tumour response. * Pregnancy or breast feedin.g * Patients with an iron overload disease. * Patient deprived of liberty or under guardianship. * Inability to understand given information and give informed consent or undergo study procedure
References
Publications (0)
Data not yet available
No reference posted for this study.